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Objective: The aim of this work was to determine the prognostic impact of positive 
margins in early oral cavity squamous cell cancer and evaluate the utility of positive 
margin incidence as a surgical quality measure. 
Study design and setting: Retrospective analysis of the National Cancer Data Base 
Subjects and methods: Patients with oral cavity squamous cell cancer diagnosed between 
1998 and 2011 who were treated with surgical resection were sampled. Univariate and 
multivariate analyses of overall survival and incidence of positive margins were 
performed. 
Results: A total of 6,830 patients were included in the survival analysis. Overall survival 
at 5-years was 69.7%. On multivariate analysis, neck dissection (HR 0.79, 95% CI 0.76-
0.94) and treatment at academic/research institutions (HR 0.88, 95% CI 1.01-0.99) were 
associated with improved survival, while positive margins (HR 1.27, 95% CI 1.08-1.49), 
insurance through Medicare (HR 1.45, 95% CI 1.25-1.69) or Medicaid (HR 1.96, 95% CI 
1.60-2.39), and adjuvant radiotherapy (HR 1.31, 95% CI 1.16-1.49), or adjuvant 
chemotherapy (HR 1.34, 95% CI 1.03-1.75) were associated with compromised survival. 
A total of 20,602 early oral cancer patients were identified for analysis of factors 
associated with positive margins. Margin status was reported in 94.8% of cases, and 
positive margins occurred in 7.5% of those cases. Incidence of positive margins by 
institution varied from 0% to 43.8%, with median incidence of 7.1%. Positive margins 
were associated with clinical factors including stage II disease (OR 1.75; 95% CI 1.55-
1.98), intermediate grade (OR 1.20; 95% CI 1.04-1.37), high grade (OR 1.68; 95% CI 
1.39-2.03), and floor of mouth (OR 1.78; 95% CI 1.52-2.08), buccal mucosa (OR 2.06 
95% CI 1.59-2.68), and retromolar locations (OR 2.40, 95% CI 1.85-3.11). Positive 
II 
 
margins were also associated with treatment at non-academic cancer centers (OR 1.23; 
95% CI 1.04-1.44) and institutions with low oral cancer case volume (OR 1.45; 95% CI 
1.23-1.69). 
Conclusion: Positive margins portend a poor prognosis in early oral squamous cell 
cancer. The incidence of positive margins is associated with clinicopathologic factors as 
well as treatment and institution factors and can serve as an effective surgical quality 
measure for early oral cavity squamous cell cancer.
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Introduction: 
 
Oral Cavity Squamous Cell Cancer 
Epidemiology:  
Head and neck cancer is a significant cause of mortality in the United States, with 
approximately 53,000 cases and 11,500 deaths predicted in 2014. Combining the sub-
sites of the oral cavity, pharynx and larynx, head and neck cancer is the 10th most 
common cancer in the United States accounting for approximately 3% of all adult 
malignancies1. The oral cavity is the most common site of head and neck cancer and oral 
cavity squamous cell cancer (OCSCC) accounts for the vast majority of oral cancer cases 
in the United States with approximately 27,000 cases and 5,500 deaths predicted in 
20142. OCSCC is 4 times more common in males than females, and occurs more 
frequently in African Americans1,3. It is primarily a disease of the adult population, with 
95% of cases occurring in patients over 40 years and 45% in patients over 65 years4.  
The majority of OCSCC cases are related to alcohol or tobacco use and are 
preventable5. The incidence of oral cancer in the United States has been decreasing over 
the last 3 decades, a trend thought to be related to decreasing smoking rates6. However, 
this trend is non-uniform among various demographic and social groups, suggesting 
continued need for education and early detection and prevention programs, particularly in 
groups of low socioeconomic status7. Multiple studies have found that public knowledge 
of oral cancer signs and symptoms is low8-12. Furthermore, despite decreasing overall 
incidence, the stage at presentation of oral cancer has remained constant over the last 
several decades13 and the largest contributor to delay in diagnosis has been the period 
between patients first noticing a lesion and subsequently presenting to a care provider14. 
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These trends suggest that improved awareness of oral cancer could lead to decreased 
incidence as well as earlier diagnosis, and that increased educational and awareness 
efforts could be practical and cost-effective strategies to decrease the burden of this 
preventable disease.   
 
Clinical Presentation 
OCSCC is frequently asymptomatic and therefore often does not prompt patient 
self-referral in its early stages15. The most common sites for tumor formation within the 
oral cavity are the tongue (40%) and the floor of mouth (30%), although OCSCC is 
known to present in other sites, including the lip, gum, buccal mucosa, and retromolar 
trigone16. Approximately 60% of patients with OCSCC present with only localized 
disease and approximately 30% present with regional lymph node involvement or distant 
metastases4.  
 OCSCC frequently arises from one of several premalignant lesions. Leukoplakia 
is a white patch or plaque which cannot be removed and cannot be attributed to a pre-
existing disease process17. Approximately 20% of leukoplakias represent an invasive 
squamous cell carcinoma or a carcinoma in situ at the time of presentation18, and non-
malignant leukoplakias have a rate of transformation to squamous cell carcinoma of 
approximately 1% per year19. Likewise, erythroplakia is defined as a red patch or plaque 
which cannot be removed and is not attributable to a pre-existing disease process. 
Erythroplakia carries a worse prognosis than leukoplakia, with 90% of lesions 
representing invasive OCSCC or carcinoma in situ and many of the remaining 10% 
exhibiting mild to moderate dysplasia15. Therefore, any unidentified red or white oral 
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lesion demands prompt evaluation, and many non-malignant lesions require surgical 
removal. 
 
Diagnosis and Staging 
Patients with oral lesions suspicious for OCSCC should be evaluated with a 
thorough history and physical examination including visual and tactile examination of the 
nasal cavity, oral cavity, oropharynx, and neck, as well as indirect mirror or direct 
fiberoptic examination of the larynx and hypopharynx. Histologic diagnosis is made with 
fine needle aspiration. Imaging studies (PET or CT) may be indicated to identify 
metastases to the neck lymph node basin or to sites of the lower aerodigestive tract20. 
Primary tumor  
T0 No evidence of primary tumor 
T1 Tumor is ≤ 2 cm in size 
T2 Tumor is > 2 cm and ≤ 4 cm in size 
T3 Tumor is > 4 cm 
T4a Tumor is growing into nearby structures, including the bones of the 
jaw of face, deep muscles of tongue, facial skin, maxillary sinus, or 
for lip cancers, the floor of mouth or inferior alveolar nerve 
T4b Tumor is growing into deeper tissues, including the pterygoid plates, 
skull base, masticator space, or surrounds the carotid artery. 
Lymph nodes  
N0 No lymph node involvement 
N1 One ipsilateral lymph node involved, ≤ 3 cm in size 
N2a One ipsilateral lymph node involved, > 3 cm and ≤ 6 cm in size 
N2b Two or more ipsilateral lymph nodes involved, all ≤ 6 cm in size 
N2c At least one contralateral lymph node involved, ≤ 6 cm in size 
N3 At least one lymph node involved and > 6 cm in size 
Distant metastasis  
M0 No distant spread 
M1 Distant metastasis present 
 
Table 1: Staging schema for OCSCC. Adapted from the American Cancer Society21. 
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Staging of OCSCC is done by TNM classification (Table 1). Overall stage 1 
disease refers to T1N0M0 tumors, stage 2 to T2N0M0, stage 3 to T3N0M0 or T1-
3N1M0, and stage 4 to any T4, N2, N3, or M1 lesions21. “Early stage” in this work refers 
to stage 1 and 2 disease, and includes only tumors of diameter < 4 cm without invasion 
into adjacent structures, lymph node involvement, or distant metastasis. 
 
Treatment  
When possible, the treatment for OCSCC is surgical resection, with adjuvant 
post-operative radiotherapy (RT) or chemoradiotherapy (CRT) indicated for certain high 
risk clinical or pathologic features22. Adjuvant RT is usually recommended in the 
treatment of patients whose tumors are pathologically staged T3, T4, N2, or N3 or exhibit 
perineural invasion or vascular embolism, while CRT is usually recommended for cases 
of extracapsular nodal spread or positive margins which cannot be re-resected. The 
majority of patients with OCSCC present with early stage (stage I or II) disease and are 
treated with surgical resection alone, with adjuvant therapy only indicated for positive 
resection margins and several other high risk features23,24. Therefore, the success of 
treatment of OCSCC, particularly in its early stages, depends on the adequacy of surgical 
management.  
 
Prognosis 
Prognosis in OCSCC depends on many factors including patient age, stage at 
diagnosis, and primary site of disease. Average 5-year relative survival for patients with 
OCSCC is approximately 65%25,26. Patients with early stage OCSCC have a 5-year 
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survival ranging from approximately 75% for tongue and floor of mouth cancers to 93% 
for lip cancers26. 
The effects of several pathologic and clinical factors on survival in early OCSCC 
are unknown or debated.  Histologic grade was previously thought not to affect prognosis 
in early OCSCC but recent reports have suggested a more important role27. Some reports 
suggest that patients treated for head and neck cancer in academic or research institutions 
have favorable outcomes compared to those treated in community cancer centers, 
mirroring trends in cancers of other tissues28. Ipsilateral neck dissection and adjuvant RT 
or CRT are indicated for OCSCC with high risk features; however, these 
recommendations have not been validated by comprehensive prospective trial in early 
OCSCC, and the survival benefit of these interventions is unknown29. Finally, the goal of 
surgery in OCSCC is complete eradication of tumor; however, positive margins have 
been reported following up to 21% of oral cancer resections and are more common in 
oral cancer than in other cancers of the head and neck30. The effect of positive margins on 
prognosis in early OCSCC is a subject of confusion and debate31-33. 
 
Positive Margins in Early OCSCC 
A positive surgical margin refers to remaining tumor at or close to the line of 
surgical resection. For decades, there has been consensus among practicing head and 
neck surgeons that the largest cause of death in patients with squamous cell carcinomas 
of the head and neck was the failure to completely eradicate the primary tumor site31,34. 
However, there is significant evidence both to support and to refute this claim, 
particularly in the setting of OCSCC.  Several issues have complicated the analysis of 
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positive margins and their effect on prognosis in early OCSCC. Firstly, the definitions of 
“positive,” “negative,” and “close” margins vary among both head and neck surgeons and 
pathologists.  A survey of 476 members of the American Head and Neck Society 
conducted in 2005 demonstrated the variability in these definitions. In defining what 
classified a margin as “clear,” the most common response among head and neck surgeons 
was a histologically clear margin of 5 mm, selected by 46% of responders. However, 
other metrics, including an absence of ink on the tumor (14%), a 1 cm gross margin 
(11%), one microscopic high powered field (8%), and other measurements or 
combinations therein, were used by significant proportions of the surveyed group35. The 
definition of a “close” margin varied similarly. Furthermore, the pathological definition 
of tumor presence was also inconsistently defined. Carcinoma in situ at the margin was 
considered positive by 83% of respondents, whereas dysplasia at the margin was 
considered positive by 17%.  Finally, tremendous variation exists among surgeons and 
pathologists regarding what constitutes a positive margin, both in terms of width and 
pathologic or histologic characteristics35. Margin harvesting techniques differ as well, 
with some surgeons sending tumor specimen alone for margin evaluation and others 
harvesting additional tissue of varying size. This variability complicates any attempt at 
multi-institutional analysis or meta-analysis of previous work to determine the effect of 
positive margins in early OCSCC. 
 Nevertheless, there have been many studies over the last several decades 
analyzing the effects of surgical margins on patient outcomes in head and neck cancers.  
Several single-institution reports have demonstrated that positive margins portend 
significantly greater mortality and poorer prognosis.  Chen et al. reported 270 patients 
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with head and neck carcinoma of varying stages using a definition of margin adequacy of 
≥5mm.  In patients with positive margins, 5 year disease free survival rates were 7% with 
a local recurrence rate of 55%, compared to 39% and 17% for patients with negative 
margins36. Liao et al. reported a large cohort of 827 patients who had undergone surgery 
for OCSCC and reported that a standard margin of 7 mm had the highest hazard ratio 
between negative and positive resection margins, with 5-year survival rates of 68.5% and 
62.5%, respectively (p = 0.04)23.  In this study, 41% of patients had early stage disease. 
Garzino-Demo et al. reported a similar cohort of 245 patients with resected OCSCC, in 
which the 5-year survival in patients with positive margins was 47.7%, compared to 
65.0% in those with negative margins; rates of recurrence and the effects of margins for 
individual tumor stages were not reported37. Nason and colleagues reported a cohort of 
277 patients with approximately equal groups with involved, ≤ 2 mm, 3-4 mm, and > 4 
mm margins, and showed that each 1 mm increase in clear margin was independently 
associated with a decrease in 5-year risk of mortality of 8%38. These studies suggest that 
positive margins lead to poorer prognosis in OCSCC.  However, these analyses did not 
examine early OCSCC specifically and could have been confounded by the fact that 
larger or more advanced tumors or tumors which were closely related to vital structures 
would be more difficult to excise with negative margins and would incidentally have 
greater associated mortality.   
Other studies demonstrate more equivocal results regarding the association 
between positive margins survival in head and neck and oral cancers. Loree and Strong 
reported 398 patients with oral cancer, 129 of which (32%) had positive margins defined 
by a 5 mm standard. Combined, patients with positive margins had double the rate of 
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local recurrence over 5 years compared to those with negative margins (36% vs. 18%) 
and likewise had slightly decreased 5-year survival rates (52% vs 60%, p = 0.025)39. 
However, these relationships were not conserved specifically among early stage oral 
cancers (defined as T1-2, N0 tumors); while there was an increase in local recurrence 
among the positive margin group (25% vs. 17%), there was no statistically significant 
difference in 5 year survival. Jones and colleagues reported 352 patients with squamous 
cell carcinoma of the head and neck, 49 of which had positive resection margins. Patients 
with positive margins had greater risk of disease recurrence (66% vs. 47%, p = 0.03) and 
lower survival (p = 0.02), but these associations did not persist on multivariate analysis30. 
Amaral et al. reported a cohort of 193 patients with stage I and II cancer of the oral cavity 
and found no significant difference in 5 year disease free or overall survival between 
patients with positive margins and those with negative margins (p = 0.381)40.  In this 
study, positive margins were designated as the presence of carcinoma in situ at the 
margin itself.  Chen et al. reported a cohort of 407 patients with early stage OCSCC and 
demonstrated a significant difference in disease free  and overall survival at 5 years 
between pathologically positive, close, and safe margins, with 50.8%, 61.4%, and 78.2% 
disease free survival (p = 0.002) and 70.1%, 85.1%, and 91.2% overall survival (p = 
0.003), respectively. However, neither metric demonstrated statistical significance when 
accounting for the presence of other adverse clinical or pathologic features, such as 
perineural or lymphovascular invasion33. 
Prior reports investigating the effects of margin status on survival have been been 
single-institution studies with small sample sizes. These data are inconsistent and 
contradictory, and few studies have examined positive margins specifically in early stage 
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OCSCC. As a result, the impact of positive margins in early OCSCC remains a subject of 
debate. A standardized, population-level analysis of the association between margin 
status and survival would therefore be very informative in the treatment of this disease. 
 
Quality measures 
Care quality standards are essential for clinical and economic success of 
oncologic practice in the evolving global healthcare environment41. As healthcare in the 
United States moves towards a value-based care system, the importance of quality 
indicators and their role in determining care and reimbursement schemata will continue to 
grow. The Patient Protection and Affordable Care Act already includes provisions for 
reduction of hospital payments based on failures in certain quality metrics for certain 
conditions, such as 30-day readmission rates for heart failure, pneumonia, and acute 
myocardial infarction admissions42. However, at this point, no quality measures have 
been adopted for surgical procedures beyond a single-institution level. Several quality 
measures have been suggested in the past for the treatment of oral cancer43. Among these 
metrics were compliance with standards of pre-operative documentation (smoking and 
alcohol history, tumor description, imaging), intraoperative documentation (frozen 
sections, pathologic reporting of tumor size, grade, lymphovascular and perineural 
invasion), and integrity of follow-up care44. No measures have been suggested that reflect 
the quality of the surgical resection itself. 
In order to be useful as a quality indicator, a metric must meet several criteria. 
The metric 1) must be feasible to measure, 2) must be under the influence of care 
providers, 3) must have strong evidence suggesting that it affects important outcomes, 
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and 4) must have variable levels, such that substandard performance exists based on 
it44,45. The status of surgical margins is largely under the control of the attending surgeon 
and surgical team46, and is one of few measures that directly reflects events occurring 
within the operating room. Positive margins have been associated with increased risk of 
disease recurrence, and successful initial surgical treatment is vital for cure in head and 
neck cancers, with risk of disease-related death increasing up to 16-fold after recurrence 
of disease47. Therefore, the incidence of positive margins is a promising candidate for 
surgical quality measurement in early OCSCC, particularly if positive margins are well-
reported, are shown to exert an independent detrimental effect on survival, and their 
incidence is shown to vary across institutions. Margin status is particularly relevant for 
early stage OCSCC, as negative margins should be achievable in nearly all cases. 
 
Statement of purpose and hypotheses 
 The aims of this work were to report the association between positive margins as 
well as other clinical or pathologic features and survival in early stage OCSCC, to report 
incidence and trends of positive margins in early OCSCC, and to evaluate the suitability 
of the incidence of positive margins as a quality measure for OCSCC surgery. Data from 
the Commission on Cancer’s National Cancer Data Base (NCDB) was examined to 
evaluate surgical margins on a population level. Owing to the large sample size afforded 
by the NCDB, this work analyzes positive margins with much greater statistical power 
than prior work, and without the potential for institutional bias. We hypothesized that 
positive margins would be independently associated with decreased survival, and that 
margin status would be well-reported and would vary with both clinical and non-clinical 
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factors. Therefore, we believe margin status meets criteria be a valuable quality measure 
for surgery in early OCSCC. 
 
Methods: 
Data source:  
The NCDB is a nationwide, hospital-based cancer registry jointly sponsored by 
the American College of Surgeon’s Commission on Cancer (CoC) and the American 
Cancer Society. It is the world’s largest oncology outcomes database, capturing 
approximately 70% of all cancer cases in the United States48. Data reported to the 
National Cancer Data Base are retrospective and compliant with the requirements of the 
Health Insurance Portability and Accountability Act49. The Yale University Institutional 
Review Board (IRB) determined this study exempt from IRB review. 
 
Study population and outcomes: 
Survival analysis  
 Patients diagnosed with stage 1 or 2 OCSCC between 2003 and 2006 were 
identified using International Classification of Diseases for Oncology, Third Edition 
(ICD-O-3) topography codes 8052, 8070-8078, 8083, and 8084. Patients who did not 
undergo surgery, those with multiple malignant primary tumors, and those with 
undocumented pathologic stage were excluded from analysis. Overall and 5-year survival 
were investigated as outcomes.  
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Quality measure analysis 
 Patients diagnosed with stage I or II OCSCC between 1998 and 2011 were 
identified using the ICD-O-3 topography codes 8052, 8070-8078, 8083, and 8084. 
Patients with multiple primary malignant tumors, undocumented pathologic stage, and 
those treated without surgery or with local tumor destruction alone were excluded from 
analysis. Status of surgical margins was investigated as an outcome variable. 
 
Predictor variables 
Factors investigated for association with overall survival included treatment 
factors (radiation, chemotherapy, neck dissection, surgical margins, facility type, facility 
case volume and insurance) and non-treatment factors (patient age, race, gender, and 
comorbidity index, and tumor primary site, pathologic stage, and grade). Radiation, 
chemotherapy, and neck dissection were reported as “received” or “not received,” and 
“regional lymph node surgery” as reported by the NCDB was considered to constitute 
neck dissection. Margin status was divided into positive margins (reported as 
“microscopic residual tumor,” “macroscopic residual tumor,” or “residual tumor, NOS,”) 
and negative margins (“No residual tumor”). Residual tumor was considered present by 
the NCDB if it was within 5 mm of the margin, and final margin status was reported in 
cases of re-resection. Facility type was based on CoC accreditation criteria and was 
divided into academic / research programs and non-academic programs, which included 
community cancer programs, comprehensive community cancer programs, and other 
programs50. Case volume was calculated as average number of oral cancer cases reported 
by an institution to the NCDB per year from 1998-2011, and was divided into categories 
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of ≤10 and >10 cases / year. Insurance was reported as private, Medicare, Medicaid, other 
government (including active military personnel, TRICARE, and Veterans Affairs), and 
no insurance. Race was reported as white, African American or black, and other. 
Comorbid conditions were analyzed using the Deyo modified Charlson comorbidity 
index51, and divided into indices of 0 and ≥1. Tumor primary site was divided into tongue 
(ICD-O-3 topography codes C020-9), lip (C000-9), floor of mouth (C040-9), gum and 
hard palate (C030-9 and C050), retromolar trigone (C062), buccal mucosa (C060) and 
other mouth, including unspecified or overlapping sites and tumors of the vestibule of 
mouth. Tumors of the base of tongue, lingual tonsil, uvula, and soft palate, traditionally 
considered sites of the oropharynx, were excluded. Tumors were staged according to 
AJCC 7th edition guidelines for pathologic staging. Grade was reported as low grade 
(well differentiated), intermediate grade (moderately differentiated), and high grade 
(poorly differentiated or anaplastic).  
Factors examined for association with margin status were patient age, race, 
gender, comorbidity index, insurance status, and travel distance to treatment facility; 
tumor primary site, stage, and grade; and facility type, location, and oral cancer case 
volume. Travel distance was determined as “great circle” distance from the center of the 
patient’s home zip code to the center of the reporting facility’s zip code, and was divided 
into categories of ≤ 50 miles and > 50 miles. Facility location was reported as one of nine 
United States Census Bureau divisions. Oral cancer case volume was calculated as the 
average number of oral cancer cases reported to the NCDB per year by institution, and 
was divided into categories of ≤ 20 cases and > 20 cases per year. All other covariates 
were analyzed as for the survival analysis. 
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Statistical analysis 
 All statistical analysis was performed using SPSS statistical software for 
Windows, version 20 (IBM, Armonk, New York). Pearson’s chi-squared tests were used 
to determine association between categorical variables and overall survival or margin 
status. Overall and 5 year survival were calculated by the Kaplan-Meier method. Cases 
were entered by the reported date of their last contact or death in months from diagnosis. 
Significance in survival differences was determined by the log-rank test. Multivariate 
analysis was conducted by Cox logistic regression with survival effects of covariates 
reported as hazard ratios (HRs). Binary logistic regression was used to identify 
independent predictors of increased positive margin incidence, with an inclusion 
threshold of p < 0.1. Patient comorbidity index was found not to contribute to the 
regression model for associations with positive margins (p = 0.328) and was removed 
from analysis to allow inclusion of cases with missing values. Effects of categorical 
variables were reported as odds ratios (ORs), while the effect of patient age was 
measured as OR per additional year. Cases with covariate data missing or unknown were 
excluded from multivariate analyses. Margins were also evaluated on an institutional 
level, sampling institutions reporting ≥10 total cases meeting our criteria to the NCDB. 
These data were displayed in box-and-whisker plots depicting the median (line within the 
box), 25th to 75th percentiles (bottom and top borders of the box), and 1.5 interquartile 
ranges above and below the 75th and 25th percentiles, respectively (whiskers), with 
outliers individually marked. The incidence of positive margins was compared between 
institutions divided by facility type and case volume, with statistical significance 
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calculated by non-parametric tests. Institutions were not weighted based on number of 
reported cases. Significance in all cases was set at p < 0.05. 
 
Results: 
Association between Margin Status and Survival 
Patient, disease and treatment characteristics of 6,830 cases of surgically treated 
early OCSCC are shown in Table 2. Age was normally distributed with a mean of 61.7 
years; 61.5% of subjects were male, and 90.4% identified as white. Overall survival at 5 
years was 69.7%. Univariate analysis of survival revealed that positive margins were 
associated with compromised survival (5-year overall survival 53.8% vs. 71.5%, p < 
0.001, Figure 1). Other treatment factors associated with decreased survival included 
radiation (p < 0.001), chemotherapy (p < 0.001), treatment at non-academic cancer 
centers (p < 0.001), treatment at low-volume facilities (p < 0.001), and surgery without 
neck dissection (p = 0.001, Table 3). The difference in 5-year overall survival between 
patients who received and did not receive neck dissections was greater in stage 2 disease 
(63.9% vs. 49.1%, respectively, p < 0.001) than in stage 1 disease (78.3% vs. 74.2%, p = 
0.001). The difference in 5-year overall survival between patients who received and did 
not receive radiation was greater in stage 1 disease (63.5% vs. 77.6%, respectively, p < 
0.001) than in stage 2 disease (53.5% vs. 61.2%, p = 0.002). 
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Treatment factors % (n=6,830) 
Neck Dissection No 50.5 
  Yes 48.3 
 Unknown 1.2 
Radiation No 80.1 
  Yes 18.0 
 Unknown 1.9 
Chemotherapy No 95.0 
  Yes 2.7 
 Unknown 2.2 
Facility typea ARP 46.6 
 
NAP 53.4 
Case volume ≤10 per year 29.1 
 >10 per year 70.9 
Insurance Private insurance 45.0 
No insurance 4.4 
 Medicaid 5.2 
 Medicare 40.1 
Other government insurance 0.8 
Unknown 4.4 
Margins Negative 88.1 
  Positive 6.8 
 Unknown 5.2 
   
Non-treatment factors % (n=6,830) 
Age ≤ 45 years 13.7 
 46-55 years 21.6 
 56-65 years 23.5 
 66-75 years 21.5 
 > 75 years 19.6 
Gender Male 61.5 
 Female 38.5 
Race White 90.4 
 AAb 3.6 
 Other race 3.9 
 Unknown 2.0 
Comorbidity score 0 81.6 
  ≥ 1 18.4 
Pathologic Stage Stage 1 64.9 
  Stage 2 35.1 
Primary Site Tongue 48.8 
 
Lip 15.8 
Floor of mouth 16.7 
Gum / hard palate 7.7 
Retromolar trigone 4.0 
Buccal mucosa 4.8 
Other mouth 2.2 
Grade Low grade 29.1 
Intermediate grade 47.3 
  High grade 11.1 
 Unknown 12.6 
Table 2: Patient, disease, and treatment characteristics of sample pool. 
aARP, academic or research program; NAP, non-academic program 
bAfrican American or Black 
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Figure 1: Kaplan-Meier curve of overall survival, positive margins vs. negative margins. 
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Treatment factors OS % (SE)a p value 
Neck Dissection No 68.0 (0.8) 0.001 
  Yes 71.7 (0.8)  
Radiation No 72.7 (0.6) < 0.001 
  Yes 57.5 (1.5)  
Chemotherapy No 69.9 (0.6) < 0.001 
  Yes 53.5 (3.9)  
Facility typeb ARP 73.5 (0.8) < 0.001 
 
NAP 66.4 (0.8)  
Case volume ≤10 per year 64.4 (1.2) < 0.001 
 >10 per year 71.8 (0.7)  
Insurance Private insurance 80.0 (0.8) < 0.001 
No insurance 78.9 (2.6)  
 Medicaid 62.2 (2.7)  
 Medicare 58.0 (1.0)  
Other government insurance 70.9 (6.7)  
Margins Negative 71.5 (0.6) < 0.001 
  Positive 53.8 (2.5)  
    
Non-treatment factors OS % (SE) p value 
Age ≤ 45 years 84.9 (1.3) < 0.001 
 46-55 years 79.3 (1.1)  
 56-65 years 73.8 (1.2)  
 66-75 years 66.3 (1.3)  
 > 75 years 48.6 (1.4)  
Gender Male 70.7 (0.8) 0.05 
 Female 68.2 (1.0)  
Race White 69.5 (0.6) 0.004 
 AAc 64.8 (3.2)  
 Other race 76.1 (2.8)  
Comorbidity score 0 72.7 (0.6) < 0.001 
  ≥ 1 56.8 (1.5)  
Pathologic Stage Stage 1 75.8 (0.7) < 0.001 
  Stage 2 58.5 (1.1)  
Primary Site Tongue 71.8 (0.8) < 0.001 
 
Lip 74.8 (1.5)  
Floor of mouth 64.3 (1.5)  
Gum / hard palate 67.4 (2.1)  
Retromolar trigone 67.7 (3.0)  
Buccal mucosa 60.4 (2.8)  
Other mouth 62.5 (4.2)  
Grade Low grade 75.0 (1.0) < 0.001 
Intermediate grade 66.9 (0.9)  
  High grade 60.1 (1.9)   
 
Table 3: Univariate survival by treatment and non-treatment characteristics. 
aOS, overall 5-year survival; SE, standard error 
bARP, academic or research program; NAP, non-academic program 
cAfrican American or Black 
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 Multivariate analysis revealed that positive margins (HR 1.27, 95% CI 1.08-1.49), 
radiation (HR 1.31, 95% CI 1.16-1.49), and chemotherapy (HR 1.34, 95% CI 1.03-1.75) 
were associated with reduced survival, while neck dissection (HR 0.85, 95% CI 0.76-
0.94) was associated with improved survival (Table 4). Treatment at non-academic 
cancer centers (HR 1.13, 95% CI 1.01-1.26) and insurance through Medicaid (HR 1.96, 
95% CI 1.60-2.39) and Medicare (HR 1.45, 95% CI 1.25-1.69) were also associated with 
compromised survival. Patient and disease features that were associated with 
compromised survival included age > 75 (HR 3.65, 95% CI 2.85-4.66), comorbidity 
score ≥ 1 (HR 1.45, 95% CI 1.30-1.61), stage 2 disease (HR 1.56, 95% CI 1.41-1.73), 
disease of the floor of mouth (HR 1.58, 95% CI 1.39-1.80) and buccal mucosa (HR 1.39, 
95% CI 1.13-1.71), intermediate grade (HR 1.27, 95% CI 1.14-1.43), and high grade (HR 
1.56, 95% CI 1.33-1.82). 
Differences between academic and non-academic cancer centers were further 
examined by evaluating differences in treatment trends between these two facility types. 
Patients treated at academic / research cancer centers were more likely to receive a neck 
dissection (p < 0.001) and less likely to receive radiation (p < 0.001) or to have positive 
margins (p < 0.001) than those treated at non-academic centers (Table 5). Pathologic 
characteristics, including stage (p = 0.9) and grade (p = 0.2), did not vary between 
patients at academic and non-academic cancer centers. 
 Luryi 20 
 
 
Treatment factors HR (95% CI)a p value 
Neck Dissection No Ref. 0.003 
  Yes 0.85 (0.76-0.94)  
Radiation No Ref. < 0.001 
  Yes 1.31 (1.16-1.49)  
Chemotherapy No Ref. 0.03 
 Yes 1.34 (1.03-1.75)  
Facility typeb ARP Ref. 0.03 
 
NAP 1.13 (1.01-1.26)  
Insurance Private insurance Ref. < 0.001 
No insurance 1.18 (0.88-1.58)  
 Medicaid 1.96 (1.60-2.39)  
 Medicare 1.45 (1.25-1.69)  
Other government insurance 1.42 (0.83-2.42)  
Margins Negative Ref. 0.005 
  Positive 1.27 (1.08-1.49)   
    
Non-treatment factors   
 Age ≤ 45 years Ref. < 0.001 
 46-55 years 1.29 (1.03-1.62)  
 56-65 years 1.69 (1.35-2.10)  
 66-75 years 2.03 (1.59-2.59)  
 > 75 years 3.65 (2.85-4.66)  
 Comorbidity score 0 Ref. < 0.001 
  ≥ 1 1.45 (1.30-1.61)  
 Pathologic Stage Stage 1 Ref. < 0.001 
  Stage 2 1.56 (1.41-1.73)  
 Primary Site Lip Ref. < 0.001 
 Tongue 1.31 (0.97-1.76)  
 Floor of mouth 1.58 (1.39-1.80)  
 Gum / hard palate 1.11 (0.93-1.33)  
 Retromolar trigone 1.17 (0.91-1.50)  
 Buccal mucosa 1.39 (1.13-1.71)  
 Other mouth 1.62 (1.18-2.22)  
 Grade Low grade Ref. < 0.001 
 Intermediate grade 1.27 (1.14-1.43)  
  High grade 1.56 (1.33-1.82)  
 
Table 4: Multivariate analysis of treatment and non-treatment factors’ associations with 
overall survival. Variables which were not significant contributors to the multivariate 
model (p > 0.05) are not shown. 
aHR, adjusted hazard ratio 
bARP, academic or research program; NAP, non-academic program 
cAfrican American or Black 
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Treatment characteristic 
ARPs 
(%) 
NAPs 
(%) 
p value 
Neck Dissection 
 
59.2 40.1 < 0.001 
Radiation 
 
15.7 20.7 < 0.001 
Chemotherapy 
 
2.9 2.7 0.7 
Positive margins  5.5 8.6 < 0.001 
Case volume >10 per year 94.8 50.1 < 0.001 
Insurance Private insurance 48.6 45.9 < 0.001 
No insurance 5.7 3.8  
 Medicaid 6.5 4.5  
 Medicare 38.3 45.1  
Other government insurance 0.9 0.8  
 
Table 5: Comparison of treatment factors between academic / research programs (ARPs) 
and non-academic programs (NAPs). 
 
Incidence of Positive Margins and Quality of Care  
Patient, disease, and facility characteristics of 20,602 cases of early OCSCC 
receiving surgical treatment are shown in Table 6. Age was normally distributed with a 
mean age of 61.7 years; 61.5% of patients were male, while 91.2% self-identified as 
white. Margin status was reported in 94.8% of cases, and 7.5% of those reported positive 
margins. On univariate analysis, factors associated with increased incidence of positive 
margins included treatment at non-academic cancer programs and at institutions with oral 
cancer case volume ≤ 20 cases per year (p < 0.001, Table 7).  
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Characteristic  % (n = 20602) 
 Average age  61.7 years 
 Gender Male 61.5 
 Female 38.5 
 Race White 91.2 
 AAb 3.7 
Other race 3.1 
 Comorbidity index 0 48.3 
 ≥1 11.8 
Unknown 39.9 
 Stage Stage 1 66.1 
 Stage 2 33.9 
 Site Tongue 46.5 
 Lip 18.4 
Floor of mouth 17.1 
Gum / hard palate 7.6 
Retromolar trigone 3.7 
Buccal mucosa 4.1 
Other mouth  2.4 
 Grade Low grade 30.8 
 Intermediate grade 46.1 
High grade 10.3 
 Insurance Private insurance 45.4 
No insurance 4.4 
Medicaid 4.9 
Medicare 39.8 
Other government insurance 0.8 
 Facility typec ARP 44.5 
NAP 55.5 
 Volume ≤20 cases / year 52.3 
>20 cases / year 47.7 
 Travel distance ≤50 miles 79.0 
>50 miles 16.9 
 Location South Atlantic 22.1 
Middle Atlantic 12.1 
New England 4.6 
East North Central 16.3 
East South Central 8.6 
West North Central 9.0 
West South Central 9.7 
Mountain 4.5 
Pacific 13.0 
 Margins Negative 87.7 
Positive 7.1 
Unknown / unreported 5.2 
 
Table 6: Demographic, disease, and treatment characteristics of NCDB sample pool. 
Percentages may not sum to 100% due to missing or unreported data. 
bAfrican American or Black 
cARP, academic / research cancer program; NAP, non-academic cancer program 
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Characteristic 
  
na 
% Positive 
margins 
 
p-value 
 Gender Male 12135 7.6 NS 
 Female 7495 7.3  
 Race White 17814 7.4 0.002 
 AAb 711 10.5  
Other race 605 7.1  
 Comorbidity index 0 9571 7.0 0.008 
 ≥1 2396 8.6  
 Stage Stage 1 13012 5.8 < 0.0005 
 Stage 2 6518 10.9  
 Site Tongue 9118 6.0 < 0.0005 
 Lip 3625 5.7  
Floor of mouth 3340 10.3  
Gum / hard palate 1458 8.2  
Retromolar trigone 711 13.2  
Buccal mucosa 803 11.3  
Other mouth 475 10.9  
 Grade Low grade 6052 6.3 < 0.0005 
 Intermediate grade 9004 8.0  
High grade 1984 10.7  
 Insurance Private insurance 9054 6.7 < 0.0005 
No insurance 865 8.7  
Medicaid 964 8.4  
Medicare 7920 8.0  
Other government insurance 159 15.1  
 Facility typec ARP 8494 6.0 < 0.0005 
NAP 11036 8.6  
 Volume ≤20 cases / year 10377 8.8 < 0.0005 
>20 cases / year 9153 5.9  
 Travel distance ≤50 miles 15562 7.8 < 0.0005 
>50 miles 3154 5.7  
 Location South Atlantic 4468 7.5 < 0.0005 
Middle Atlantic 2453 6.7  
New England 926 10.9  
East North Central 3165 7.7  
East South Central 1744 6.4  
West North Central 1779 5.3  
West South Central 1650 8.1  
Mountain 864 6.1  
Pacific 2481 8.9  
Total  19630 7.5  
 
Table 7: Univariate analysis of factors associated with positive margins. 
aTotals may be unequal due to missing data; cases with missing margin status are 
excluded 
bAfrican American or Black  
cARP, academic / research cancer program; NAP, non-academic cancer program 
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Institutional incidence of positive margins among 541 facilities reporting at least 
10 total cases to the NCDB ranged from 0% to 43.8%, with a median incidence of 7.1% 
(Figure 2). The median incidence of positive margins among institutions with oral cancer 
case volume >20 per year was 5.9% compared to 7.7% for institutions reporting ≤ 20 
cases/year (p < 0.0005). The median incidence of positive margins among academic / 
research cancer centers was 6.4% compared to 7.7% for non-academic cancer centers (p 
= 0.028). Over 50% of facilities documented margin status in 100% of reported cases, 
and 93% of facilities documented margin status in at least 90% of reported cases. 
 
Figure 2: Institutional incidence of positive margins among facilities reporting ≥20 cases 
to the NCDB. Case volume in OCSCC cases annually (average); line within box, median; 
bottom and top borders of box, 25th and 75th percentiles; whiskers, 1.5 interquartile ranges 
above and below the 75th and 25th percentiles; outliers individually marked. NAP, non-
academic cancer program; ARP, academic / research cancer program. 
 
Multivariate analysis (Table 8) revealed that clinical factors most strongly 
associated with positive margins were stage II disease (OR 1.75, 95% CI 1.55-1.98), high 
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grade disease (OR 1.68 relative to low grade disease, 95% CI 1.39-2.03), and floor of 
mouth (OR 1.78, 95% CI 1.52-2.08), retromolar trigone (OR 2.40, 95% CI 1.85-3.11), 
and buccal mucosa (OR 2.06, 95% CI 1.59-2.68) tumor sites. Treatment at non-academic 
cancer centers (OR 1.23, 95% CI 1.08-1.44) and treatment in New England (OR 1.42 
relative to South Atlantic reference, 95% CI 1.08-1.86) were also independently 
associated with increased incidence of positive margins, while treatment at institutions 
reporting >20 oral cancer cases annually (OR 0.70; 95% CI 0.59-0.82) and travel distance 
> 50 miles (OR 0.81; 95% CI 0.67-0.98) were associated with decreased positive margin 
incidence. 
Characteristic OR (95% CI) p value 
 Stage Stage 1 Ref. < 0.0005 
 Stage 2 1.75 (1.55-1.98)  
 Grade Low grade Ref. < 0.0005 
 Intermediate grade 1.20 (1.04-1.37)  
 High grade 1.68 (1.39-2.03)  
 Site Tongue Ref. < 0.0005 
 Lip 1.07 (0.88-1.31)  
Floor of mouth 1.78 (1.52-2.08)  
Gum / hard palate 1.46 (1.15-1.84)  
Retromolar trigone 2.40 (1.85-3.11)  
Buccal mucosa 2.06 (1.59-2.68)  
Other mouth 1.73 (1.23-2.44)  
 Facility typeb ARP Ref. 0.013 
NAP 1.23 (1.04-1.44)  
 Volume ≤20 cases / year Ref. < 0.0005 
>20 cases / year 0.70 (0.59-0.82)  
 Travel distance ≤50 miles Ref. 0.028 
>50 miles 0.81 (0.67-0.98)  
 Location South Atlantic Ref. 0.001 
 Middle Atlantic 0.91 (0.73-1.14)  
 New England 1.42 (1.08-1.86)  
East North Central 1.00 (0.82-1.22)  
East South Central 0.98 (0.76-1.25)  
West North Central 0.71 (0.54-0.92)  
West South Central 1.10 (0.87-1.40)  
 Mountain 0.96 (0.70-1.33)  
 Pacific 1.26 (1.03-1.55)  
 
Table 8: Multivariate analysis of factors associated with positive marginsa. 
aVariables without significant association to margin status (p < 0.05) are not shown. 
bARP, academic / research cancer program; NAP, non-academic cancer program 
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Discussion: 
The association of positive margins with reduced survival is widely reported, but 
whether this is a direct result of residual disease or a consequence of other correlated 
clinicopathologic or surgical features has been unclear31,33. There is also tremendous 
variation in the reported strength of association between positive margins and outcomes, 
with associated decreases in 5-year survival ranging from 0% to over 80%23,32,36. As a 
result, there has been ongoing debate regarding the optimal level of aggressiveness of 
surgery for oral cancer, with some reports recommending surgical de-escalation52. Our 
population level analysis provides compelling evidence about the importance of margin 
status in oral cancer and confirms the association between positive margins and poor 
outcomes. These findings suggest that aggressive resection to achieve negative margins is 
justified in OCSCC. In addition, these findings support the role of margin status in 
determining adjuvant therapy use in early OCSCC, although the difference in margin 
positivity between treatment institutions also suggests that more complete resection is 
possible in some patients. 
Analyzing differences in survival associated with other treatment factors may 
reveal opportunities to improve outcomes through systems-based approaches. Overall 5-
year survival in the NCDB data was consistent with reports over the last several decades 
at approximately 70%25,53,54 and was associated with multiple treatment and non-
treatment factors. Our data revealed associations between survival and healthcare 
delivery factors such as insurance and treating facility type, suggesting potential 
differences in quality of care that may be viable targets for quality improvement efforts. 
For example, care at academic / research cancer centers was associated with improved 
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survival compared to care at non-academic centers, consistent with prior reports on head 
and neck and other cancer outcomes28,55. This may be due to increased provider expertise, 
as suggested by the lower incidence of positive margins and greater oral cancer case 
volume among these academic centers, or increased surgical aggressiveness, as evidenced 
by the greater proportion of patients receiving neck dissection. However, high case 
volume was not associated with increased survival in the NCDB data despite traditionally 
being viewed as a surrogate marker for high-quality surgical care56. Patients insured 
through Medicare or Medicaid experienced compromised outcomes compared to similar 
patients with private insurance. Previous reports have similarly shown that lack of 
insurance and federal insurance are independently associated with compromised 
outcomes in head and neck cancers57. This troubling trend may reflect inconsistent 
treatment and follow-up due to tenuous access to healthcare or worse baseline health, 
which has been reported in these patients58. Identifying the underlying causes of the 
survival differences associated with these healthcare delivery factors could enable 
improvement of outcomes through the spread of optimal care practices.  
The National Comprehensive Cancer Network (NCCN) currently recommends 
selective neck dissection of at minimum levels I-III for tumors of depth ≥ 4 mm and at 
the discretion of the surgeon for tumors of depth ≥ 2 mm24. However, these guidelines are 
based on consensus with no supporting high-level evidence59 and the optimal treatment of 
a clinically N0 neck in early OCSCC with no adverse features remains a subject of 
controversy60. Neck dissection was associated with increased survival in our data, 
suggesting that END could confer a survival benefit to patients for whom it is not 
currently indicated, especially since patients who underwent neck dissection may have 
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had a greater initial burden of disease. The difference in survival was greater for patients 
with stage 2 disease compared to those with stage 1 disease, suggesting a greater 
prevalence of resected occult neck disease. However, the association between END and 
improved survival in our data should be interpreted with caution, since patients with 
clinically N0 disease who underwent END and were found to have occult nodal 
metastasis would have been pathologically restaged and thus removed from this sample 
pool, leading to a sampling bias. Although prospective data is lacking, a recent meta-
analysis of limited existing data also reported improved survival among patients with 
stage 1 or 2 oral cancer and no additional high-risk features treated with END compared 
with observation of the neck61. Further study with prospective trials is necessary to 
elucidate the role of END in early OCSCC. 
Conversely, radiation and chemotherapy were associated with decreased survival. 
Although positive margins are the most common indication for adjuvant CRT in early 
OCSCC, other high risk pathologic features, such as lymphovascular or perineural 
invasion, also result in the recommendation for adjuvant therapies24. We were unable to 
adjust for perineural and lymphovascular invasion in this analysis because these 
characteristics were not reported in the NCDB. Although these factors are inconsistently 
reported and their prognostic impact is debatable, they could confound the impact of 
radiation and chemotherapy on survival62-64. In addition, use of radiotherapy or 
chemotherapy could be a surrogate marker for less aggressive resection in patients with 
very localized disease. This could explain our finding that radiotherapy was associated 
with a greater decrease in survival in stage 1 than in stage 2 disease. Further study is 
necessary to determine the role of these adjuvant therapies in early stage OCSCC. 
 Luryi 29 
 
Among other covariates evaluated, patient age, pathologic stage, comorbid 
conditions and primary tumor site were the most influential independent predictors of 
survival.  The deleterious effects of advanced age and tumor stage (which depends 
entirely on tumor size in early stage OCSCC) are well documented in oral cancer25,64.  
Tumors of the lip were associated with the best prognosis while tumors of the floor of the 
mouth were associated with poorest prognosis (HR 1.58 compared to tumors of the lip, p 
< 0.001), likely reflecting ease of resection and propensity toward invasion. 
Histologic grade was found to carry an independent predictive role in survival, 
with high and intermediate grade disease independently associated with compromised 
survival compared with low grade disease. The prognostic relevance of grade in oral 
cancer has been a subject of debate for decades. Broder’s classification system of 
squamous cell carcinomas of the head and neck was the first widely used grading system 
for OCSCC and was based on the proportion of differentiated to undifferentiated cells.  
Until recently, Broder’s schema and other purely cytologic analyses were thought to have 
little prognostic value, and more complex grading systems incorporating other histologic 
signs (mitotic activity, lymphovascular invasion, mode of invasion, etc.) were favored as 
more accurate predictors of prognosis27.  More recently, several single-institution reports 
have suggested that histologic grade alone is an independent prognostic indicator65.  The 
present data from the NCDB supports these reports and suggests that poor differentiation 
is related to increased tumor aggression and invasion. It is therefore possible that 
treatment guidelines could be improved if modified to consider tumor degree of 
differentiation. 
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The NCDB data analyzed in this study allow a representative assessment of 
surgical margins in early OCSCC in the United States. Positive margins were present in 
7.5% of cases, which is within the wide range demonstrated in prior reports on 
OCSCC33,38,66. Patients with stage II disease, intermediate or high grade tumors, and 
tumors located in the mouth floor, buccal mucosa, or retromolar trigone were at high risk 
for positive margins, reflecting larger, more aggressive, and poorly accessible tumors, 
leading to greater technical difficulty of resection27,65,67,68.  
Margin status also varied significantly with non-clinical factors, including the 
type, location, oral cancer case volume, and travel distance of treating facilities. 
Treatment at institutions reporting >20 cases per year was associated with a 33% 
decrease in the incidence of positive margins and an independent decrease in the risk of 
positive margins compared to institutions with ≤ 20 cases per year. The incidence of 
positive margins was also lower among patients treated at academic cancer centers. These 
findings are consistent with prior data reporting compromised outcomes in head and neck 
and other cancers that are managed at small, non-academic facilities, and may be 
attributable to increased expertise, experience and resources in high volume academic 
settings28,69. Patients treated in New England were at greater risk of positive margins, 
possibly because a greater proportion of patients in New England were treated at low-
volume facilities than in any other region (data not shown), or because of regional 
differences in physician practices or disease severity at presentation. Patients at greater 
distance from their treating facilities also had a lower incidence of positive margins, 
possibly due to travel to high-volume institutions. These associations between positive 
margins and non-clinical factors suggest potential variation in quality of care. 
 Luryi 31 
 
Easily quantifiable quality measures are vital for the success of OCSCC treatment 
but are lacking in many surgical fields70. A 2005 committee of the American Head and 
Neck Society developed several quality measures for treatment of oral cancer based on 
contemporary pretreatment evaluation, treatment, and post-treatment surveillance 
guidelines43. However, the quality measures suggested measured adherence to guidelines, 
standards of care and documentation rather than strictly surgical outcomes. We sought to 
evaluate the utility of the incidence of positive margins as a quality measure for early 
stage oral cancer. The status of surgical margins in early oral cancer is under the direct 
control of the attending surgeon and treating care team44. Our data show that margin 
status is well-reported and easily measured, with 95% of our sample having a 
documented margin status and a median rate of margin documentation among reporting 
institutions of 100%. This is consistent with one prior retrospective study of tongue 
cancer from Texas M.D. Anderson Cancer Center, which found the institutional rate of 
margin status documentation to be similarly high at 97.4%44. Furthermore, significant 
variability in positive margin incidence was present among reporting facilities, with some 
reporting no positive margins and others reporting positive margins in up to 44% of 
cases, which could be considered sub-standard care. The incidence of positive margins 
also varied significantly by facility type, case volume, and location, further suggesting 
differences in quality of care. Finally, we showed that positive margins are associated 
with compromised survival on a population level in our survival analysis. In the absence 
of a prospective trial, which is impractical in the context of margin status, this is the 
strongest available evidence that positive margins lead to poor outcomes. Based on these 
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results, the incidence of positive margins meets criteria to be a useful quality measure for 
treatment of early OCSCC.  
This study is the largest contemporary report of surgical margins in early stage 
OCSCC. However, several limitations of this study should be considered in interpreting 
its results. This study is subject to shortcomings common to all large retrospective 
database studies, including the potential for errors in reporting and inconsistencies in 
institutional reporting habits. Due to the retrospective nature of the study, the physician 
and patient decisions prior to and during surgery are unknown, so more detailed 
exploration of technical factors leading to positive margins is not possible. In addition, a 
significant proportion of cases were excluded from multivariate analysis because 
covariate data was unknown or missing. The reasons for these missing data and whether 
they alter the sample pool are unknown.  Finally, there was no centralized review of 
pathology to determine margin status in the NCDB, and no possibility of controlling for 
variation among surgeons in margin harvesting techniques or for variation among 
pathologists what constitutes a positive margin. Positive margins are explicitly defined as 
<5 mm in the NCDB reporting guidelines. However, variations in surgical and pathologic 
technique could have contributed to the variation in positive margin incidence and were 
not accounted for in this analysis. 
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Conclusion: 
Although tumor eradication is the goal of oral cancer surgery, 7.5% of early 
OCSCC resections have positive final tumor margins and this leads to decreased survival. 
Care at non-academic cancer centers and insurance through Medicare and Medicaid are 
also associated with reduced survival, which may reflect issues of access to health care. 
The incidence of positive margins ranged from 0% to 44% by institution and is related to 
many demographic and clinical factors including stage of disease, type of treating facility 
and geographic region. Because margins are well-reported, affect outcomes, are under the 
surgeon’s control, and vary widely among institutions, the incidence of positive margins 
is a promising surgical quality indicator for early OCSCC. 
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